Germline mutation in the RAD51B gene confers predisposition to breast cancer

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Golmard, Lisa ^a,b   Caux Moncoutier, Virginie ^a   Davy, Grégoire ^a   Al Ageeli, Essam ^a   Poirot, Brigitte ^a   Tirapo, Carole ^a   Michaux, Dorothée ^a   Barbaroux, Catherine ^a   d'Enghien, Catherine D ^a   Nicolas, André ^a   Castéra, Laurent ^a   Sastre Garau, Xavier ^a   Stern, Marc Henri ^a,b   Houdayer, Claude ^a,b,c   Stoppa Lyonnet, Dominique ^a,b,c  

^a INSTITUT CURIE   (France)

^b INSTITUT CURIE   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Breast cancer; Genetic predisposition; Ovarian cancer; RAD51 paralogs; RAD51B

Indexed keywords

XRCC3 PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DNA SPLICING; ENHANCED MISMATCH MUTATION ANALYSIS; FAMILY HISTORY; FEMALE; GENE; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MUTATION RATE; MUTATIONAL ANALYSIS; ONSET AGE; OVARY CANCER; PARALOGY; PENETRANCE; RAD51B GENE; RAD51C GENE; RAD51D GENE; SEQUENCE ANALYSIS; XRCC2 GENE; XRCC3 GENE;

BREAST NEOPLASMS; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; EXONS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HUMANS; IMMUNOHISTOCHEMISTRY; PEDIGREE; RNA SPLICING;

EID: 84885516070     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-484     Document Type: Article

References (42)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90. 10.3322/caac.20107, 21296855.
2. Claus EB, Risch N, Thompson WD. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 1991, 48:232-242. 1683001, 1990835.
3. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266:66-71. 10.1126/science.7545954, 7545954.
4. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995, 378:789-792. 10.1038/378789a0, 8524414.
5. Pharoah PD, Antoniou AC, Easton DF, Ponder BA. Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med 2008, 358:2796-2803. 10.1056/NEJMsa0708739, 18579814.
6. Walsh T, King MC. Ten genes for inherited breast cancer. Cancer Cell 2007, 11:103-105. 10.1016/j.ccr.2007.01.010, 17292821.
7. Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R, Chagtai T, Jayatilake H, Ahmed M, Spanova K, North B, McGuffog L, Evans DG, Eccles D, Easton DF, Stratton MR, Rahman N, Breast Cancer Susceptibility Collaboration (UK) Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 2006, 38:1239-1241. 10.1038/ng1902, 17033622, Breast Cancer Susceptibility Collaboration (UK).
8. Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, Reid S, Spanova K, Barfoot R, Chagtai T, Jayatilake H, McGuffog L, Hanks S, Evans DG, Eccles D, Easton DF, Stratton MR, Breast Cancer Susceptibility Collaboration (UK) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 2007, 39:165-167. 10.1038/ng1959, 2871593, 17200668, Breast Cancer Susceptibility Collaboration (UK).
9. Foulkes WD. Inherited susceptibility to common cancers. N Engl J Med 2008, 359:2143-2153. 10.1056/NEJMra0802968, 19005198.
10. Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, De Die-Smulders C, Persky N, Grompe M, Joenje H, Pals G, Ikeda H, Fox EA, D'Andrea AD. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002, 297:606-609. 10.1126/science.1073834, 12065746.
11. Levitus M, Waisfisz Q, Godthelp BC, de Vries Y, Hussain S, Wiegant WW, Elghalbzouri-Maghrani E, Steltenpool J, Rooimans MA, Pals G, Arwert F, Mathew CG, Zdzienicka MZ, Hiom K, De Winter JP, Joenje H. The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J. Nat Genet 2005, 37:934-935. 10.1038/ng1625, 16116423.
12. Reid S, Schindler D, Hanenberg H, Barker K, Hanks S, Kalb R, Neveling K, Kelly P, Seal S, Freund M, Wurm M, Batish SD, Lach FP, Yetgin S, Neitzel H, Ariffin H, Tischkowitz M, Mathew CG, Auerbach AD, Rahman N. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet 2007, 39:162-164. 10.1038/ng1947, 17200671.
13. Suwaki N, Klare K, Tarsounas M. RAD51 paralogs: roles in DNA damage signalling, recombinational repair and tumorigenesis. Semin Cell Dev Biol 2011, 22:898-905. 10.1016/j.semcdb.2011.07.019, 21821141.
14. Vaz F, Hanenberg H, Schuster B, Barker K, Wiek C, Erven V, Neveling K, Endt D, Kesterton I, Autore F, Fraternali F, Freund M, Hartmann L, Grimwade D, Roberts RG, Schaal H, Mohammed S, Rahman N, Schindler D, Mathew CG. Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet 2010, 42:406-409. 10.1038/ng.570, 20400963.
15. Shamseldin HE, Elfaki M, Alkuraya FS. Exome sequencing reveals a novel Fanconi group defined by XRCC2 mutation. J Med Genet 2012, 49:184-186. 10.1136/jmedgenet-2011-100585, 22232082.
16. Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Niederacher D, Freund M, Lichtner P, Hartmann L, Schaal H, Ramser J, Honisch E, Kubisch C, Wichmann HE, Kast K, Deissler H, Engel C, Müller-Myhsok B, Neveling K, Kiechle M, Mathew CG, Schindler D, Schmutzler RK, Hanenberg H. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 2010, 42:410-414. 10.1038/ng.569, 20400964.
17. Loveday C, Turnbull C, Ramsay E, Hughes D, Ruark E, Frankum JR, Bowden G, Kalmyrzaev B, Warren-Perry M, Snape K, Adlard JW, Barwell J, Berg J, Brady AF, Brewer C, Brice G, Chapman C, Cook J, Davidson R, Donaldson A, Douglas F, Greenhalgh L, Henderson A, Izatt L, Kumar A, Lalloo F, Miedzybrodzka Z, Morrison PJ, Paterson J, Porteous M, et al. Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet 2011, 43:879-882. 10.1038/ng.893, 21822267.
18. Park DJ, Lesueur F, Nguyen-Dumont T, Pertesi M, Odefrey F, Hammet F, Neuhausen SL, John EM, Andrulis IL, Terry MB, Daly M, Buys S, Le Calvez-Kelm F, Lonie A, Pope BJ, Tsimiklis H, Voegele C, Hilbers FM, Hoogerbrugge N, Barroso A, Osorio A, Giles GG, Devilee P, Benitez J, Hopper JL, Tavtigian SV, Goldgar DE, Southey MC, Breast Cancer Family Registry Rare mutations in XRCC2 increase the risk of breast cancer. Am J Hum Genet 2012, 90:734-739. 13, 10.1016/j.ajhg.2012.02.027, 3322233, 22464251, Breast Cancer Family Registry.
19. Hilbers FS, Wijnen JT, Hoogerbrugge N, Oosterwijk JC, Collee MJ, Peterlongo P, Radice P, Manoukian S, Feroce I, Capra F, Couch FJ, Wang X, Guidugli L, Offit K, Shah S, Campbell IG, Thompson ER, James PA, Trainer AH, Gracia J, Benitez J, van Asperen CJ, Devilee P. Rare variants in XRCC2 as breast cancer susceptibility alleles. J Med Genet 2012, 49:618-620. 10.1136/jmedgenet-2012-101191, 23054243.
20. Johnson J, Healey S, Khanna KK, Chenevix-Trench G, kConFab Mutation analysis of RAD51L1 (RAD51B/REC2) in multiple-case, non-BRCA1/2 breast cancer families. Breast Cancer Res Treat 2011, 129:255-263. 10.1007/s10549-011-1539-6, 21533530, kConFab.
21. Caux-Moncoutier V, Castéra L, Tirapo C, Michaux D, Rémon MA, Laugé A, Rouleau E, De Pauw A, Buecher B, Gauthier-Villars M, Viovy JL, Stoppa-Lyonnet D, Houdayer C. EMMA, a cost- and time-effective diagnostic method for simultaneous detection of point mutations and large-scale genomic rearrangements: application to BRCA1 and BRCA2 in 1,525 patients. Hum Mutat 2011, 32:325-334. 10.1002/humu.21414, 21120943.
22. Align-GVGD. http://agvgd.iarc.fr/agvgd_input.php.
23. Tavtigian SV, Deffenbaugh AM, Yin L, Judkins T, Scholl T, Samollow PB, de Silva D, Zharkikh A, Thomas A. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet 2006, 43:295-305. 2563222, 16014699.
24. SIFT. http://sift.jcvi.org/.
25. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009, 4:1073-1081. 10.1038/nprot.2009.86, 19561590.
26. Polyphen-2. http://genetics.bwh.harvard.edu/pph2/.
27. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. A method and server for predicting damaging missense mutations. Nat Methods 2010, 7:248-249. 10.1038/nmeth0410-248, 2855889, 20354512.
28. Exome Variant Server. http://evs.gs.washington.edu/EVS/.
29. 1000 Genomes. http://www.1000genomes.org/.
30. Houdayer C, Caux-Moncoutier V, Krieger S, Barrois M, Bonnet F, Bourdon V, Bronner M, Buisson M, Coulet F, Gaildrat P, Lefol C, Léone M, Mazoyer S, Muller D, Remenieras A, Révillion F, Rouleau E, Sokolowska J, Vert JP, Lidereau R, Soubrier F, Sobol H, Sevenet N, Bressac-de Paillerets B, Hardouin A, Tosi M, Sinilnikova OM, Stoppa-Lyonnet D. Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico/in vitro studies on BRCA1 and BRCA2 variants. Hum Mutat 2012, 33:1228-1238. 10.1002/humu.22101, 22505045.
31. Heim S, Nilbert M, Vanni R, Floderus UM, Mandahl N, Liedgren S, Lecca U, Mitelman F. A specific translocation, t(12;14)(q14-15;q23-24), characterizes a subgroup of uterine leiomyomas. Cancer Genet Cytogenet 1988, 32:13-17. 10.1016/0165-4608(88)90305-6, 3355995.
32. Schoenmakers EF, Huysmans C, van de Ven WJ. Allelic knockout of novel splice variants of human recombination repair gene RAD51B in t(12;14) uterine leiomyomas. Cancer Res 1999, 59:19-23.
33. Date O, Katsura M, Ishida M, Yoshihara T, Kinomura A, Sueda T, Miyagawa K. Haploinsufficiency of RAD51B causes centrosome fragmentation and aneuploidy in human cells. Cancer Res 2006, 66:6018-6024. 10.1158/0008-5472.CAN-05-2803, 16778173.
34. Thomas G, Jacobs KB, Kraft P, Yeager M, Wacholder S, Cox DG, Hankinson SE, Hutchinson A, Wang Z, Yu K, Chatterjee N, Garcia-Closas M, Gonzalez-Bosquet J, Prokunina-Olsson L, Orr N, Willett WC, Colditz GA, Ziegler RG, Berg CD, Buys SS, McCarty CA, Feigelson HS, Calle EE, Thun MJ, Diver R, Prentice R, Jackson R, Kooperberg C, Chlebowski R, Lissowska J, et al. A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet 2009, 41:579-584. 10.1038/ng.353, 2928646, 19330030.
35. Orr N, Lemnrau A, Cooke R, Fletcher O, Tomczyk K, Jones M, Johnson N, Lord CJ, Mitsopoulos C, Zvelebil M, McDade SS, Buck G, Blancher C, Trainer AH, James PA, Bojesen SE, Bokmand S, Nevanlinna H, Mattson J, Friedman E, Laitman Y, Palli D, Masala G, Zanna I, Ottini L, Giannini G, Hollestelle A, Ouweland AM, Novaković S, Krajc M, , et al. KConFab Consortium Genome-wide association study identifies a common variant in RAD51B associated with male breast cancer risk. Nat Genet 2012, 44:1182-1184. 10.1038/ng.2417, 3722904, 23001122, KConFab Consortium.
36. Zucchero TM, Cooper ME, Maher BS, Daack-Hirsch S, Nepomuceno B, Ribeiro L, Caprau D, Christensen K, Suzuki Y, Machida J, Natsume N, Yoshiura K, Vieira AR, Orioli IM, Castilla EE, Moreno L, Arcos-Burgos M, Lidral AC, Field LL, Liu YE, Ray A, Goldstein TH, Schultz RE, Shi M, Johnson MK, Kondo S, Schutte BC, Marazita ML, Murray JC. Interferon regulatory factor 6 (IRF6) gene variants and the risk of isolated cleft lip or palate. N Engl J Med 2004, 351:769-780. 10.1056/NEJMoa032909, 15317890.
37. Dickson SP, Wang K, Krantz I, Hakonarson H, Goldstein DB. Rare variants create synthetic genome-wide associations. PLoS Biol 2010, 8:e1000294. 10.1371/journal.pbio.1000294, 2811148, 20126254.
38. dbSNP. http://www.ncbi.nlm.nih.gov/SNP/.
39. He XF, Wei W, Su J, Yang ZX, Liu Y, Zhang Y, Ding DP, Wang W. Association between the XRCC3 polymorphisms and breast cancer risk: meta-analysis based on case-control studies. Mol Biol Rep 2012, 39:5125-5134. 10.1007/s11033-011-1308-y, 22161248.
40. Thompson ER, Boyle SE, Johnson J, Ryland GL, Sawyer S, Choong DY, Chenevix-Trench G, Trainer AH, Lindeman GJ, Mitchell G, James PA, Campbell IG, kConFab Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients. Hum Mutat 2012, 33:95-99. 10.1002/humu.21625, 21990120, kConFab.
41. Romero A, Pérez-Segura P, Tosar A, García-Saenz JA, Díaz-Rubio E, Caldés T, de la Hoya M. A HRM-based screening method detects RAD51C germ-line deleterious mutations in Spanish breast and ovarian cancer families. Breast Cancer Res Treat 2011, 129:939-946. 10.1007/s10549-011-1543-x, 21537932.
42. Loveday C, Turnbull C, Ruark E, Xicola RM, Ramsay E, Hughes D, Warren-Perry M, Snape K, Eccles D, Evans DG, Gore M, Renwick A, Seal S, Antoniou AC, Rahman N, Breast Cancer Susceptibility Collaboration (UK) Germline RAD51C mutations confer susceptibility to ovarian cancer. Nat Genet 2012, 44:475-476. author reply 476, 10.1038/ng.2224, 22538716, Breast Cancer Susceptibility Collaboration (UK).